BridgeBio Pharma, Inc. (BBIO) › Operating Cash FlowBridgeBio Pharma, Inc. (BBIO) — Operating Cash FlowAnnual figures by period end, from SEC filings.2017-12-31: -$40.49M2018-12-31: -$136.64M2019-12-31: -$253.59M2020-12-31: -$399.71M2021-12-31: -$497.93M2022-12-31: -$419.49M2023-12-31: -$527.72M2024-12-31: -$520.73M2025-12-31: -$445.91M-$445.91M2017-12-31Operating Cash Flow (USD)2025-12-31Period endedOperating Cash FlowChange YoYSource filing2025-12-31-$445.91M—2026-02-24From 2025-01-012024-12-31-$520.73M—2026-02-24From 2024-01-012023-12-31-$527.72M—2026-02-24From 2023-01-012022-12-31-$419.49M—2025-02-20From 2022-01-012021-12-31-$497.93M—2024-02-22From 2021-01-012020-12-31-$399.71M—2023-02-23From 2020-01-012019-12-31-$253.59M—2022-02-25From 2019-01-012018-12-31-$136.64M—2021-02-25From 2018-01-012017-12-31-$40.49M—2020-03-03From 2017-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)